Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited has reported encouraging outcomes from its XanaCIDD depression trial, revealing significant improvement in depression scores and consistent therapeutic effects of their drug Xanamem. This novel treatment shows potential in controlling brain cortisol levels which may lead to lasting benefits for patients with major depressive disorder (MDD). The company is actively discussing next steps for the development of Xanamem for MDD treatment with regulatory authorities and potential partners.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
